Skip to main content
Top

02-11-2023 | SCLC | Expert Interview | Article | F. Hoffmann-La Roche Ltd.

ESMO23: Small-cell lung cancer highlights

print
PRINT
insite
SEARCH
Host:
medwireNews

medwireNews is an independent medical news service provided by Springer Healthcare Ltd.

Dr. Luis Paz-Ares and Prof. Andrea Ardizzoni discuss the top small-cell lung cancer abstracts presented at ESMO 2023. 

Abstracts discussed include:

Presentation date: Tuesday 24th October 2023

Speakers

  • Dr. Luis Paz-Ares
    University Hospital October 12, Madrid, Spain. Read more
  • Prof. Andrea Ardizzoni 
    University Bologna, Italy. Read more

Speaker disclosures

Dr. Luis Paz-Ares

  • Speaker fees: AZ, Beigene, BMS, Daichii, Lilly, Medscape, MSD, PER, Pharmamar, Roche.
  • Board member: Altum sequencing, Genomica, Stab Therapeutics.
  • Advisory boards: Amgen, AZ, Bayer, Beigene, BMS, Daichii, GSK, Janssen, Lilly, Medscape, Merck Serono, Mirati, MSD, Novartis, PER, Pfizer, Pharmamar, Roche, Sanofi, Takeda.
  • Other: Altum sequencing, Genomica, ONCOSUR.
  • Personal: Altum sequencing, Amgen, AZ, Bayer, Beigene, BMS, Daichii, Genomica, GSK, Janssen, Lilly, Medscape, Merck Serono, Mirati, MSD, Novartis, PER, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Stab Therapeutics, Amgen.
  • Institutional: Alkermes, AZ, BMS, Daiichi Sankyo, Janssen-cilag international NV, Lilly, Merck Sharp & Dohme corp, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Tesaro.
  • Coordinating PI: Alkermes, Amgen, AZ, BMS, Daiichi Sankyo, Janssen-cilag international NV, Lilly, Merck Sharp & Dohme corp, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Tesaro.
  • Financial interest: Alkermes, Amgen, AZ, BMS, Daiichi Sankyo, Janssen-cilag international NV, Lilly, Merck Sharp & Dohme corp, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Tesaro.

Prof. Andrea Ardizzoni

  • Speaker fees: BMS, Astra Zeneca, MSD, Eli Lilly, Novartis
  • Advisory boards: Janssen, AstraZeneca, BMS, Sanofi, Eli Lilly, Takeda, Bayer, Novartis, MSD

Financial disclosure

This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Disclaimer

Any information provided and opinions expressed do not necessarily reflect the views of Springer Medizin GmbH. Springer Medizin GmbH and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.

Related topics

Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare